Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC

Kirollos Hanna

Cancer Screening in Primary Care: An Evidence-Based Review of Outpat…

UNC Lineberger Comprehensive Cancer Center

N. Robertson

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

Year in Review: Breast Cancer

Dana-Farber Cancer Institute

P. Tarantino

2023 Menopause Update

Yale School of Medicine

M. Minkin

ASCO® 2023 Summary: "eBC Expert Panel Discussion on Key Trials Inclu…

Insights from 2023 ASCO® Annual Meeting

H. Rugo, K. Jhaveri

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

Neoadjuvant Chemo for HR+ BC: Year in Review

Total Health

C. Ma

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-…

2024 ESMO Annual Meeting Insights Hub

P. Tarantino

Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Awar…

Insights from ESMO Breast 2024 Annual Meeting

H. Rugo

SABCS 2023 Insights: "Biology or Stage? Tailoring Treatment for Prem…

Insights from 2023 SABCS

K. Kalinsky

Vogl,NY on How to Ask Good Questions at Medical Meetings

Vogl, NY

S. Vogl

CDK4/6 Inhibitor Therapy in Early-Stage HR+/HER2- BC

Scripps Health

S. Sammons

Cancer Screening Molecular Tools

Fengting Yan

What's New in Breast Cancer?

Dana-Farber Cancer Institute

S. Tolaney

ASCO® 2024 Noteworthy Abstracts in Breast Cancer

Sara Tolaney

H. Rugo

Optimizing Adjuvant Treatment in High-Risk HR+/HER2- eBC: Patient Se…

Wassim Mchayleh

ESMO Breast 2024 Summary: "Community Oncologists Highlights"

Insights from ESMO Breast 2024 Annual Meeting

S. Tolaney, H. Rugo

ESMO 2024 Noteworthy Abstracts in Breast Cancer

Sara Tolaney

H. Rugo

ASCO® 2024 Insights: "NATALEE Trial - Baseline Characteristics and E…

2024 ASCO® Annual Meeting Insights Hub

D. Yardley